Renal & Urology News15d
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
Merilog administered subcutaneously 5 to 10 minutes before mealtime helps improve glycemic control. (HealthDay News) — The US Food and Drug Administration has approved Merilog (insulin-aspart ...
WebMD15d
FDA OKs First Fast-Acting Insulin Biosimilar for Diabetes
Merilog, made by Sanofi-Aventis, is a rapid-acting insulin biosimilar (similar to Novo Nordisk’s Novolog) that helps control blood sugar spikes when taken five to 10 minutes before a meal.
healthday16d
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric ...
Managed Healthcare Executive16d
FDA Approves First Biosimilar of Novolog
Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...
Interesting Engineering17d
FDA approves first-ever rapid-acting insulin biosimilar for diabetes treatment
The U.S. Food and Drug Administration (FDA) has approved Merilog, a biosimilar to the widely used insulin product Novolog (insulin aspart), to enhance glycemic control in adults and children with ...
Daily18d
Sanofi's Merilog Receives USFDA Approval as Biosimilar to Novolog for Diabetes Management
New Delhi: Sanofi has received U.S. Food and Drug Administration (FDA) approval for Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for improving glycemic control in adults ...
Monthly Prescribing Reference18d
FDA Approves Merilog, a Rapid-Acting Insulin Biosimilar Product
Merilog 100units/mL is supplied as both a 10mL multi-dose vial as well as a 3mL single-patient-use prefilled pen. The Food and Drug Administration (FDA) has approved Merilog (insulin-aspart-szjj ...
Medscape18d
FDA Okays New Rapid-Acting Biosimilar Insulin for Diabetes
The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for treating adults and children with diabetes.
Pharm Exec19d
FDA Approves Sanofi’s Rapid Acting Insulin Biosimilar Merilog for Diabetes
The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for improving glycemic control in adults and pediatric patients with diabetes mellitus. The regulatory ...
BioSpace19d
Sanofi Challenges Novo With First FDA Nod for NovoLog Biosimilar
Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for price caps and, potentially, the rise of the mammoth GLP-1 market. Like its ...
Business Insider21d
FDA approves Sanofi biosimilar product for treatment of diabetes
The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. “Merilog ...